Immuneering Corporation (NASDAQ:IMRX) Stock Has Consensus Target Price of $15.67 According to Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $15.67.

Several analysts recently commented on IMRX shares. Chardan Capital raised Immuneering to a “strong-buy” rating in a research note on Monday, August 3rd. HC Wainwright reiterated a “buy” rating on shares of Immuneering in a research note on Friday, October 30th. Wall Street Zen cut Immuneering from a “sell” rating to a “strong sell” rating in a report on Saturday. Needham & Company LLC boosted their target price on shares of Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, September 21st.

Hedge Funds Weigh In On Immuneering

Several institutional investors have recently added to or reduced their stakes in IMRX. Aberdeen Group plc acquired a new stake in shares of Immuneering during the third quarter worth approximately $3,214,000. PVG Asset Management Corp acquired a new position in shares of Immuneering in the 1st quarter worth approximately $773,000. Fisher Asset Management LLC boosted its holdings in shares of Immuneering by 31.3% in the 3rd quarter. Fisher Asset Management LLC now owns 115,954 shares of the company’s stock worth $475,000 after acquiring an additional 27,621 shares in the last quarter. Weiss Asset Management LP bought a new stake in Immuneering during the 1st quarter worth approximately $464,000. Finally, Alps Advisors Inc. grew its position in Immuneering by 29.6% during the 3rd quarter. Alps Advisors Inc. now owns 85,109 shares of the company’s stock worth $349,000 after acquiring an additional 19,451 shares during the last quarter. 67.65% of the stock is owned by institutional investors.

Immuneering Stock Performance

NASDAQ:IMRX opened at $3.65 on Tuesday. The firm’s 50-day moving average is $4.09 and its 200-day moving average is $4.77. The company has a market cap of $236.37 million, a price-to-earnings ratio of -3.54 and a beta of 0.49. Immuneering has a 52-week low of $3.35 and a 52-week high of $8.48.

Immuneering (NASDAQ:IMRX) last released its earnings results on Thursday, October 29th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.06). Equities analysts predict that Immuneering will post -1.19 EPS for the current year.

About Immuneering

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.